(Q42436769)

31 October 2017

title

Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine (English)

1 reference

31 October 2017

0 references

Shanshan Liu

1

1 reference

31 October 2017

Paul M Beringer

2

1 reference

31 October 2017

Levita Hidayat

3

1 reference

31 October 2017

Adupa P Rao

4

1 reference

31 October 2017

Stan Louie

5

1 reference

31 October 2017

Gilbert J Burckart

6

1 reference

31 October 2017

Bertrand Shapiro

7

1 reference

31 October 2017

publication date

29 May 2008

1 reference

The Journal of Clinical Pharmacology

31 October 2017

published in

1 reference

31 October 2017

volume

48

1 reference

31 October 2017

issue

8

1 reference

31 October 2017

page(s)

957-965

1 reference

Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients

31 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

Measurement of basal, substrate induced and total P-glycoprotein activity in bronchoalveolar lavage T-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

Levofloxacin pharmacokinetics in adult cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

Usefulness of 2D echo Doppler in the preoperative assessment of cystic fibrosis patients who are candidates for lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

Identification of functionally variant MDR1 alleles among European Americans and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

CFTR Genotype as a Predictor of Prognosis in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008319707

21 January 2018

Identifiers

DOI

10.1177/0091270008319707

1 reference

31 October 2017

1 reference